surgery) is mandatory. Prognosis is generally excellent. Recurrence is a rare event (6%), but it can occur in the form of invasive disease.

**2022-RA-195-ESGO**

**MIRNA-125B EXPRESSION IN EPITHELIAL OVARIAN CANCER**

1Shashank Shekar, 2Praveen Sharma, 3Kiran Khandosyia, 4Pratibha Singh, 5Manu Goyal, 6Charu Sharma, 7Dharmveer Yadav. 1Obstetrics and Gynecology, All India Institute of Medical Sciences, Jodhpur, India; 2Biochemistry, All India Institute of Medical Sciences, Jodhpur, India; 3All India Institute of Medical Sciences, Jodhpur, India

Introduction/Background Most (70%) epithelial ovarian cancers (EOCs) are diagnosed late. Non-invasive biomarkers that facilitate early disease detection are needed. The microRNAs (miRNAs) represent a new class of biomarkers whose expression is aberrant in various human cancers and miRNA-125B has been shown to be overexpressed in EOC. This study was conducted to investigate plasma miRNA 125B as a diagnostic biomarker in EOC.

Methodology A pre-surgical venous blood sample of all patients with clinically diagnosed ovarian tumors and likely to undergo surgery was drawn. After histopathological confirmation of benign or malignant epithelial ovarian tumor of surgically resected specimen, patients were enrolled into the study and their blood sample were further analysed for miRNA-125B expression. Patients with epithelial ovarian cancer on histopathological examination were defined as cases and those with benign pathology report served as controls. Commercial kit were used to isolate RNA including miRNA from serum samples. The RNA were then be reverse-transcribed into cDNA using cDNA synthesis kit as per the manufacturer's protocol. The Ct values of housekeeping U6 snRNA and test mir-125b were used to calculate the delta Ct (ΔCt) values between test and reference genes in both controls and cases.

Optimal cytoreductive surgery, <1 cm visible disease (VD), is associated with improved survival. Survival rates in patients with a suboptimal cytoreduction are equivocal. Surgery can be extensive and associated with significant morbidity and mortality. Tumour resectability and patient co-morbidity affect treatment planning. Pre-operative predictive models may provide an objective measure to aid this decision-making process. This study aimed to externally validate the ability of two pre-operative predictive models (Sudan et al 2014, 2017) to determine the likelihood of suboptimal cytoreductive surgery (>1 cm VD) and any residual disease in the treatment of AOC in a London teaching hospital.

Methodology Between January 2018–June 2020, 236 patients were treated for AOC in a London Teaching Hospital. 145 had cytoreductive surgery, 6 had incomplete records and were excluded. Suidan et al (2014, 2017) model's resectability score 1 (RS1) (suboptimal cytoreduction) and resectability score 2 (RS2) (any residual disease) were used to score patients against clinical and radiological criteria. Receiver operating characteristic (ROC) curve analysis was used to determine the accuracy of models.

Results The optimal cytoreductive surgery rate was 88.28% (n=128), 80.69% (n=117) had no visible disease, Both RS1 and RS2 models predicted surgical outcomes. RS1 AUC 0.862 (95% CI: 0.8189 to 0.9067, P<0.0001), RS2 AUC 0.869 (95% CI 0.8263 to 0.9126, P<0.0001).

Conclusion In our centre, Suidan et al’s RS1 and RS2 models were able to predict cytoreductive outcomes. Predictive models may help determine patient suitability for cytoreductive surgery in AOC treatment.

**2022-RA-209-ESGO**

**A RETROSPECTIVE STUDY OF OVARIAN CANCER AMONG ELDERLY – EVALUATION AND PROGNOSIS**

11Miriam Rivka Brezin, 22Shira Peleg Hasson, 33Elia Shachar, 41Dan Grisaro, 41,24Ido Laskov, 41Nadav Michael, 41Lyn Adar, 41Avigail Harpaz, 41Adi Diner, 41Bar Levy, 51Ido Wolf, 22Tamar Safra. 1Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 4Gynecologic Oncology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Introduction/Background Half of epithelial ovarian cancer (EOC) are diagnosed above age 65. Women over 70 have higher morbidity and mortality. Our real-life retrospective study evaluates elderly with EOC.

Methodology Women above 70 were classified as ‘elderly’ (N=233) (71–93), and bellow 70 – ‘control cohort’ (N=755) (24–70). Treatment schedule used (6–8 cycles) were 3-weekly regimen (PC-3W) – carboplatin AUC-6 + Paclitaxel 175 mg/m² on day 1 of a 21-day cycle, and weekly regimen (PC-1W) - carboplatin AUC-2 + paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle.

Results When comparing elderly to control median overall survival (mOS) was 41.26 (33.05–63.87) vs. 69.78 (50.07–75.01) months respectively (p<0.0001). No statistical differences were shown when comparing toxicities except for grade 2 anemia – 36.49% vs. 19.67% respectively (p<0.0001) and grade 2 alopecia – 44.81% vs. 60.52% respectively (p<0.0001). The use of PC-1W vs. PC-3W was 44.29% vs. 47.14% in the elderly compared to 39.03% vs. 60.3% in the control (p<0.0001). Among the elderly mOS

**2022-RA-198-ESGO**

**A VALIDATION STUDY OF TWO PRE-OPERATIVE PREDICTIVE MODELS IN THE TREATMENT PLANNING OF ADVANCED OVARIAN CANCER**

Amy MacDonald Shearer, Saurabhi Phadnis, James Dilley. Barts Health NHS Trust, London, UK

Introduction/Background In advanced ovarian cancer (AOC) optimal cytoreductive surgery, <1 cm visible disease (VD), is

Abstracts

Int J Gynecol Cancer: first published as 10.1136/ijgc-2022-ESGO.482 on 20 October 2022. Downloaded from http://ijgc.bmj.com/ on December 20, 2022 by guest. Protected by copyright.